Henry Ford Cancer Institute Senior Leadership

The Henry Ford Cancer Institute is led by an esteemed group of physicians, clinicians, researchers, and advisors, each of whom do their part to ensure excellence in cancer care, education, and research.

Steven Kalkanis MDSteven N. Kalkanis, M.D.
Medical Director, Henry Ford Cancer Institute

Dr. Kalkanis is the medical director of the Henry Ford Cancer Institute, Chair of the Department of Neurosurgery, and Co-Director of the Henry Ford Neuroscience Institute. Under Dr. Kalkanis’ leadership, the Henry Ford Cancer Institute become one of the largest cancer centers in the country, treating more than 8,000 new cancer patients and over 100,000 patient visits each year across Henry Ford sites in southeastern and south central Michigan.

A nationally recognized neurosurgeon [[https://www.henryford.com/physician-directory/k/kalkanis-steven#provider-about-section] specializing in brain tumor surgery, Dr. Kalkanis has been involved in numerous clinical trials for brain tumors and has authored over 125 peer reviewed publications.

Dr. Kalkanis holds leadership positions in the most prominent of oncologic academic and advocacy organizations, most recently receiving one of the profession’s highest honors in being named director of the American Board of Neurological Surgery. He has led national efforts to spearhead national treatment guidelines for metastatic brain tumors, and several neurosurgical clinical practice guidelines.

He completed his neurosurgical training at Massachusetts General Hospital. He graduated with highest honors from Harvard University, where he was awarded the John Harvard Scholarship, and then Harvard Medical School, where he served as class marshal and received the Linnane Prize for highest academic achievement.

Spencer HooverSpencer Hoover
Vice President and Executive Director, Henry Ford Cancer Institute

Spencer Hoover, a decorated U.S. Army veteran, serves as vice president and executive director of the health system’s Henry Ford Cancer Institute and cancer care services.

In this role, Hoover has developed an infrastructure that supports the development of strategic and tactical plans to achieve the financial, clinical, and quality goals for the Henry Ford Cancer Institute.

Hoover has played an integral role in the development and operational design of the Cancer Institute’s Precision Medicine Program. This effort, in collaboration with a multidisciplinary team of Henry Ford specialists, resulted in the Cancer Institute joining Vice President Joe Biden’s Cancer Moonshot Initiative last summer.

During four years of service as an infantry soldier in the Army’s 82nd Airborne Division, Hoover was awarded six medals, four special qualification badges and three combat patches. He served combat missions in Iraq and Afghanistan.

Medical Oncology

Philip Kuriakose, M.D., FACP,
Interim Division Head, Hematology/Oncology, Henry Ford Cancer Institute

Dr. Kuriakose is board certified in Hematology and Oncology and has been nationally recognized as an expert on hematologic malignancies and for his work as an educator in the field. He led Henry Ford’s Hemophilia Treatment Center to collaborate with centers in India, which won international recognition. Additionally, Dr. Kuriakose continues to be active in areas of patient care, scholarly activity and national committee membership. Dr. Kuriakose is a graduate of the Christian Medical College in India and completed his medical training at Henry Ford Hospital in Detroit and the Mayo Clinic.

Radiation Oncology

Benjamin Movsas, M.D.
Chair, Department of Radiation Oncology, Henry Ford Cancer Institute

Dr. Movsas is a nationally recognized expert in the field of radiation oncology, stereotactic radiosurgery, lung cancer, prostate cancer, and quality of life issues pertaining to cancer. He has published extensively in many prestigious medical journals and regularly presents his research findings at some of the nation’s top medical meetings. Dr. Movsas holds leadership positions in the most prominent academic organizations, most recently as chair of the American Society for Radiation Oncology (ASTRO) Annual Meeting Scientific Program Committee, the largest international meeting in the field of radiation oncology.

Surgical Oncology

David S. Kwon, M.D.
Division Head, Surgical Oncology, Henry Ford Cancer Institute

Dr. David Kwon is a board-certified surgeon and fellowship-trained surgical oncologist, His clinical interests include pancreatic cancer surgery and cytoreductive cancer surgery for HIPEC. Dr. Kwon received his undergraduate degree in Biological Sciences from Columbia University and earned his medical degree from the University of California, San Diego. He completed his residency in general surgery at Henry Ford Hospital where he received multiple research and clinical awards. He completed a surgical oncology fellowship at the University of Texas, M.D. Anderson Cancer Center where he developed clinical expertise in the multidisciplinary care of cancer patients.

Research

Margot LaPointe, Ph.D.
Vice President of Research, Henry Ford Health System

Dr. LaPointe oversees the basic/translational, clinical and population/healthcare research at Henry Ford, as well an internal grant program, the clinical trials office and clinical research center, biostatistics core, research space, and the Department of Research Administration. She closely works with the Assistant Deans for Research at Wayne State University School of Medicine and the Wayne State University Vice President of Research. Dr. LaPointe received her degrees from Louisiana State University, the University of North Carolina, and the University Of New Orleans, LA. She completed her research fellowship at the University of California, San Francisco.

Benjamin Rybicki, Ph.D.
Senior Scientists, Department of Public Health, Henry Ford Health System

Clinical Trials

Ding Wang, M.D., Ph.D.
Associate Director, Clinical Trials Office, Henry Ford Health System

Igor Rybkin, M.D., Ph.D.
Thoracic Oncology Clinical Trials, Henry Ford Cancer Institute

Precision Medicine Program

Nadia Haque, Pharm.D., MHSA
Director, Precision Medicine, Henry Ford Cancer Institute

Dr. Haque is responsible for the design, implementation and operational management of the system-wide Precision Medicine program. In this role, she interfaces with Syapse, our precision medicine informatics partner, as well as the Henry Ford Pathology and Information Technology departments. She coordinates the molecular tumor boards with the Henry Ford Cancer Institute care pathway teams. In 2014, she completed an administrative fellowship and assumed the role of director, Group Practice Improvement within Henry Ford Medical Group in 2015.She holds a doctorate degree in Pharmacy, and a Masters in Health Services Administration.

Dhan Chitale, M.D.
Division Head, Molecular Pathology and Genomic Medicine, Henry Ford Cancer Institute

Ding Wang, M.D., Ph.D.
Associate Director, Clinical Trials Office, Henry Ford Health System

Igor Rybkin, M.D., Ph.D.
Thoracic Oncology Clinical Trials, Henry Ford Cancer Institute

Supportive Oncology Services

Michael Ryan, PSYD,
Clinical Director, Supportive Oncology Services, Henry Ford Cancer Institute

Dr. Ryan specializes in the care of cancer patients and their caregivers from diagnosis through survivorship.She graduated with her Doctorate in Clinical Psychology from the Florida School of Professional Psychology in Tampa, Florida. She completed her internship and fellowship training in Clinical Health Psychology at Henry Ford Hospital where she joined as a senior staff psychologist with the Henry Ford Cancer Institute in 2011.